Arcutis Biotherapeutics develops and sells ZORYVE topical treatments for psoriasis, atopic dermatitis, and seborrheic dermatitis. ARQT reports earnings on Wed, Nov 4, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in ARQT, 0% of them bullish and 100% bearish. In the past 30 days there were 1 dark pool print.
Prices, price targets and earnings estimates for ARQT are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARQT is in one of them and how their past ARQT trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Arcutis Biotherapeutics
Arcutis Biotherapeutics is a biopharmaceutical company based in Westlake Village, California. It develops and sells treatments for skin conditions, mainly its ZORYVE line of topical creams and foam. These products treat plaque psoriasis, atopic dermatitis, and seborrheic dermatitis in children and adults. Its customers include dermatologists, primary care practitioners, and pediatricians who prescribe them.
